Inflammation pp 464-522 | Cite as

Bradykinin-System

  • J. Garcia Leme
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 50 / 1)

Abstract

There is general agreement that inflammation is a multimediated process. In previous chapters the participation of several endogenous substances as putative mediators of inflammatory reactions has been considered. In this chapter, evidence of the involvement of hypotensive kinins, and particularly bradykinin (Bk), in such reactions will be discussed. The main scope is to evaluate to what extent kinins are contributing to the inflammatory response, as well as to assess the significance of their participation in such a complex, multimediated process.

Keywords

Permeability Migraine Aspirin Morphine Catecholamine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aarsen, P.N.: The influence of analgesic antipyretic drugs on the responses of guinea-pig lungs to bradykinin. Brit. J. Pharmacol. 27, 196–204 (1966)PubMedGoogle Scholar
  2. Abe, K., Watanabe, N., Kumagai, N., Mouri, T., Seki, T., Yoshinaga, K.: Circulating plasma kinin in patients with bronchial asthma. Experientia (Basel) 23, 626–627 (1967)Google Scholar
  3. Amundsen, E., Nustad, K.: Kinin-forming and destroying activities of saliva. Brit. J. Pharmacol. 23, 440–444 (1964)PubMedGoogle Scholar
  4. Amundsen, E., Rugstad, H. E.: Influence of some pathogenic bacteria on kinin formation and destruction. Brit. J. Pharmacol. 25, 67–73 (1965)PubMedGoogle Scholar
  5. Anderson, M.C., Schiller, W.R., Gramatica, L.: Alterations of portal venous and systemic arterial pressure during experimental acute pancreatitis. Amer. J. Surg. 117, 715–720 (1969)PubMedGoogle Scholar
  6. Ankier, S.I., Starr, M.S.: The importance of plasma kinins in the anaphylactoid reaction in rats. Brit. J. Pharmacol. 31, 331–339 (1967)PubMedGoogle Scholar
  7. Armstrong, D.: Pain. In: Erdös, E.G. (Ed.): Bradykinin, Kallidin, and Kallikrein. Handbook of Experimental Pharmacology, Vol. XXV, pp. 434–481. Berlin-Heidelberg-New York: Springer 1970Google Scholar
  8. Armstrong, D., Dry, R.M.L., Keele, C.A., Markham, J.W.: Pain-producing substances in blister fluid and in serum. J. Physiol. (Lond.) 117, 4P-5P (1952)Google Scholar
  9. Armstrong, D., Dry, R.M.L., Keele, C.A., Markham, J.W.: Observation on chemical excitants of cutaneous pain in man. J. Physiol. (Lond.) 120, 326–351 (1953)Google Scholar
  10. Armstrong, D., Jepson, J.B., Keele, C.A.: Activation by glass of pharmacologically active agents in blood various species. J. Physiol. (Lond.) 129, 80 P–81P (1955)Google Scholar
  11. Armstrong, D., Jepson, J.B., Keele, C.A., Stewart, J.W.: Developing of pain-producing substance in human plasma. Nature (Lond.) 174, 791–792 (1954)Google Scholar
  12. Armstrong, D., Jepson, J.B., Keele, C.S., Stewart, J.W.: Pain producing substance in human inflammatory exudates and plasma. J. Physiol. (Lond.) 135, 350–370 (1957)Google Scholar
  13. Armstrong, D., Mills, G.L.: Chemical characterization of kinins of human plasma. Nature (Lond.) 197, 490 (1963)Google Scholar
  14. Armstrong, D.A., Stewart, J.W.: Anti-heparin agents as inhibitors of plasma kinin formation. Nature (Lond.) 194, 689 (1962)Google Scholar
  15. Back, N., Munson, A.E., Guth, P.S.: Anaphylactic shock in dogs. J. Amer. med. Ass. 183, 260–263 (1963)Google Scholar
  16. Bagdasarian, R.A., Talamo, R.C., Coiman, R.W.: Isolation of high molecular weight activators of human plasma kallikrein. J. biol. Chem. 248, 3456–3463 (1973)PubMedGoogle Scholar
  17. Baumgarten, A., Melrose, G.J.H., Vagg, W.J.: Interactions between histamine and bradykinin assessed by continuous recording of increased vascular permeability. J. Physiol. (Lond.) 208, 669–675 (1970)Google Scholar
  18. Beraldo, W.T.: Formation of bradykinin in anaphylactic and peptone shock. Amer. J. Physiol. 163, 283–289 (1950)PubMedGoogle Scholar
  19. Bernard, A.: La pancréatite aigüe. Toxémie enzymatique. Presse méd. 67, 2351–2353 (1959)PubMedGoogle Scholar
  20. Bertelli, A.: Proteases and anti-proteasic substances in the inflammatory response. Biochem. Pharmacol. Spec. Suppl, 229–240 (1968)Google Scholar
  21. Bhalla, T.N., Sinha, J.N., Tangri, K.K., Bhargava, K. P.: Role of catecholamines in inflammation. Europ. J. Pharmacol. 13, 90–96 (1970)Google Scholar
  22. Bhoola, K.D., Schachter, M.: A comparison of serum kallikrein, bradykinin, and histamine on capillary permeability. J. Physiol. (Lond.) 149, 80 P–81P (1959)Google Scholar
  23. Bignold, L.P., Lykke, A.W. J.: Increased vascular permeability induced in synovialis of the rat by histamine, serotonin, and bradykinin. Experientia (Basel) 31, 671–672 (1975)Google Scholar
  24. Boissonas, R.A., Guttmann, S., Jaquenoud, P.A.: Synthèse de la L-arginyl-L-prolyl-prolyl-glycyl-L-phénylalanyl-L-séryl-L-prolyl-L-phénylalanyl-L-arginine, un nonapeptide présentant les proprietés de la bradykinine. Helv. chim. Acta 43, 1349–1358 (1960a)Google Scholar
  25. Boissonnas, R.A., Guttmann, St., Jaquenoud, P.A., Konzett, H., Sturner, E.: Synthesis and biological activity of peptides related to bradykinin. Experientia (Basel) 16, 326 (1960 b)Google Scholar
  26. Boissonas, R.A., Guttmann, S., Jaquenoud, P.A., Pless, J., Sandrin, E.: The synthesis of bradykinin and of related peptides. Ann. N.Y. Acad. Sci. 104, 5–14 (1963)Google Scholar
  27. Bolam, J.P., Elliott, P. N.C., Ford-Hutchinson, A.W., Smith, M.J.H.: Histamine, 5-hydroxytryp-tamine, kinins, and the anti-inflammatory activity of human plasma fraction in carrageenan-induced paw oedema in the rat. J. Pharm. (Lond.) 26, 434–440 (1974)Google Scholar
  28. Bonta, I.L., De Vos, C.J.: Presence of a slow-contraction inducing material in fluid collected from the rat paw oedema induced by serotonin. Experientia (Basel) 21, 34–38 (1965)Google Scholar
  29. Bonta, I.L., De Vos, C.J.: Significance of the kinin system in rat paw oedemas and drug effects on it. Europ. J. Pharmacol. 1, 222–225 (1967)Google Scholar
  30. Boreham, P.F.L.: In vitro studies on the mechanism of kinin formation by trypanosomes. Brit. J. Pharmacol. 34, 598–603 (1968)Google Scholar
  31. Borges, D.R., Gordon, A.H.: Kininogen and kininogenase synthesis by the liver of normal and injured rats. J. Pharm. (Lond.) 28, 44–48 (1976)Google Scholar
  32. Borges, D.R., Prado, J.L., Guimarães, J.A.: Characterization of a kinin-converting arylamino peptidase from human liver. Naunyn-Schmiedebergs Arch. Pharmacol. 281, 403–414 (1974)PubMedGoogle Scholar
  33. Briseid, K., Arntzen, F.C., Dyrud, O.K.: Inhibition of carrageenin-induced rat paw-oedema by substances causing a reduction of kininogen and prekallikrein in plasma. Acta pharmacol. (Kbh.) 29, 265–274 (1971)Google Scholar
  34. Brocklehurst, W.E., Lahiri, S.C.: The production of bradykinin in anaphylaxis. J. Physiol. (Lond.) 160, 15 P–16 P (1962)Google Scholar
  35. Brocklehurst, W.E., Zeitlin, I. J.: Determination of plasma kinin and kininogen levels in man. J. Physiol. (Lond.) 191, 417–426 (1967)Google Scholar
  36. Burch, G.E., De Pasquale, N.P.: Bradykinin, digital blood flow, and the arteriovenous anastomoses. Circulat. Res. 10, 105–115 (1962)PubMedGoogle Scholar
  37. Camargo, A.C.M., Graeff, F.G.: Subcellular distribution and properties of the bradykinin inactivation system in rabbit brain homogenates. Biochem. Pharmacol. 18, 548–549 (1969)PubMedGoogle Scholar
  38. Camargo, A.C.M., Ramalho-Pinto, F.J., Greene, L.J.: Brain peptidases: conversion and inactivation of kinin hormones. J. Neurochem. 19, 37–49 (1972)PubMedGoogle Scholar
  39. Camargo, A.C.M., Shapanka, R., Greene, L.J.: Preparation, assay, and partial characterization of a neutral endopeptidase from rabbit brain. Biochemistry 12, 1838–1844 (1973)PubMedGoogle Scholar
  40. Carr, J., Wilhelm, D.L.: The evaluation of increased vascular permeability in the skin of guineapigs. Aust. J. exp. Biol. med. Sci. 42, 511–522 (1964)PubMedGoogle Scholar
  41. Carr, J., Wilhelm, D.L.: Interspecies differences in response to polypeptides as permeability factors. Nature (Lond.) 208, 653–655 (1965)Google Scholar
  42. Carvalho, I.F., Diniz, C.R.: Kinin forming enzyme (kininogenin) in rat kidney. Ann. N.Y. Acad. Sci. 116, 912–917 (1964)Google Scholar
  43. Castania, A., Rothschild, A.M.: Lowering of kininogen in rat blood by adrenaline and its inhibition by sympatholytic agents, heparin, and aspirin. Brit. J. Pharmacol. 50, 375–389 (1974)Google Scholar
  44. Castelfranchi, P.L., Corrado, A.P.: Variações do bradicininógeno plasmático e efeitos de um inhibidor enzimatico em pancreopatias agudas expérimentais. Ciênc. Cult. 23, 505–514 (1971)Google Scholar
  45. Chapman, L.F., Goodell, H.: The participation of the nervous system in the inflammatory reaction. Ann. N.Y. Acad. Sci. 116, 990–1017 (1964)PubMedGoogle Scholar
  46. Chapman, L.F., Ramos, A.O., Goodell, H., Wolff, H.G.: Neurohumoral features of afferent fibers in man. Arch. Neurol. 4, 617–650 (1961)PubMedGoogle Scholar
  47. Cîrstea, M., Suhaciu, G., Butculescu, L.: Bradykinin and anaphylactic shock in dogs. Int. Arch. Allergy 26, 356–361 (1965)PubMedGoogle Scholar
  48. Cîrstea, M., Suhaciu, G., Butculescu, I.: Evaluation du rôle de la bradykinine dans le choc anaphylactique. Arch. int. Pharmacodyn. 159, 18–33 (1966)PubMedGoogle Scholar
  49. Cline, M.J., Melmon, K.L.: Plasma kinins and Cortisol: a possible explanation of the anti-inflammatory action of Cortisol. Science 153, 90–92 (1966)Google Scholar
  50. Cochrane, C.G., Revak, S.D., Wuepper, K.D.: Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. J. exp. Med. 138, 1564–1583 (1973)PubMedGoogle Scholar
  51. Cochrane, C.G., Wuepper, K.D.: The first component of the kinin-forming system in human and rabbit plasma. Its relationship to clotting factor XII (Hageman factor). J. exp. Med. 134, 986–1004 (1971)PubMedGoogle Scholar
  52. Coffman, J.D., Javett, S.L.: Calf blood flow and oxygen usage during bradykinin infusions. J. appl. Physiol. 18, 1003–1007 (1963)PubMedGoogle Scholar
  53. Collier, H.O.J.: La bradykinin et ses antagonists. Actualités pharmacol. 14, 51–74 (1961)Google Scholar
  54. Collier, H.O.J., Holgate, J.A., Schachter, M., Shorley, P.G.: The bronchoconstrictor action of bradykinin in the guinea-pig. Brit. J. Pharmacol. 15, 290–297 (1960)PubMedGoogle Scholar
  55. Collier, H.O.J., James, G.W.L.: Bradykinin and slow reacting substance in anaphylactic bron-choconstriction of the guinea pig in vivo. J. Physiol. (Lond.) 185, 71P–72 P (1966)Google Scholar
  56. Collier, H.O.J., Lee, I.R.: Nociceptive responses of guinea-pigs to intradermal injections of bradykinin and kallidin-10. Brit. J. Pharmacol. 21, 155–164 (1963)PubMedGoogle Scholar
  57. Collier, H.O.J., Schneider, C.: Nociceptive response to prostaglandins and analgesic actions of aspirin and morphine. Nature (New Biol.) 236, 141–143 (1972)Google Scholar
  58. Collier, H.O.J., Shorley, P.G.: Analgesic antipyretic drugs as antagonists of bradykinin. Brit. J. Pharmacol. 15, 601–610 (1960)PubMedGoogle Scholar
  59. Collier, H.O.J., Shorley, P.G.: Antagonism by mefenamic and flufenamic acids of the bronchoconstrictor action of kinins in the guinea-pig. Brit. J. Pharmacol. 20, 345–351 (1963)PubMedGoogle Scholar
  60. Corrado, A.P., Reis, M.L., Carvalho, I.F., Diniz, C.R.: Bradykininogen and bradykinin in the cardiovascular shock produced by proteolytic enzymes. Biochem. Pharmacol. 15, 959–970 (1966)PubMedGoogle Scholar
  61. Cotran, R.S., Majno, G.: A light and electron microscopic analysis of vascular injury. Ann. N.Y. Acad. Sci. 116, 750–764 (1964)PubMedGoogle Scholar
  62. Crunkhorn, P., Meacock, S.C. R.: Mediators of the inflammation induced in the rat paw by carrageenin. Brit. J. Pharmacol. 42, 392–402 (1971)Google Scholar
  63. Davies, G.E., Holman, G., Johnston, T. P., Lowe, J.S.: Studies on kallikrein: failure of some antiinflammatory drugs of affect release of kinin. Brit. J. Pharmacol. 28, 212–217 (1966)PubMedGoogle Scholar
  64. Dawson, W., Starr, M.S., West, G.B.: Inhibition of anaphylactic shock in the rat by antihistamines and ascorbic acid. Brit. J. Pharmacol. 27, 249–255 (1966)PubMedGoogle Scholar
  65. De Duve, C.: Lysosomes and cell injury. In: Thomas, L., Uhr, J.W., Grant, L. (Eds.): Injury, Inflammation, and Immunity, pp. 283–311. Baltimore: Williams & Wilkins Comp. 1964Google Scholar
  66. De Duve, C., Pressman, B.C., Gianetto, R., Wattiaux, R., Appelmans, F.: Tissue fractionation studies: intracellular distribution patterns of enzymes in rat liver tissue. Biochem. J. 60, 604–617 (1955)Google Scholar
  67. Deutsch, H.F., Diniz, C.R.: Some proteolytic activities of snake venoms. J. biol. Chem. 216, 17–26 (1955)PubMedGoogle Scholar
  68. Diniz, C.R., Carvalho, I.F.: A micromethod for determination of bradykininogen under several conditions. Ann. N.Y. Acad. Sci. 104, 77–89 (1963)PubMedGoogle Scholar
  69. Diniz, C.R., Carvalho, I.F., Reis, M.L., Corrado, A.P.: Bradykininogen in some experimental conditions. In: Rocha e Silva, M., Rothschild, H.A. (Eds.): Int. Symp. on Vaso-Active Polypeptides: Bradykinin and Related Kinins, pp. 15–20. São Paulo: Edart 1967Google Scholar
  70. Diniz, C.R., Carvalho, I.F., Ryan, J., Rocha e Silva, M.: A micromethod for the determination of bradykininogen in blood plasma. Nature (Lond.) 192, 1194–1195 (1961)Google Scholar
  71. Di Rosa, M., Giroud, J.P., Willoughby, D.A.: Studies on the mediators of the acute inflammatory response induced in rats in different sites by carrageenin and turpentine. J. Path. 104, 15–29 (1971)PubMedGoogle Scholar
  72. Di Rosa, M., Sorrentino, L.: The mechanism of the inflammatory effect of carrageenin. Europ. J. Pharmacol. 4, 340–342 (1968)Google Scholar
  73. Di Rosa, M., Sorrentino, L.: Some pharmacodynamic properties of carrageenin in the rat. Brit. J. Pharmacol. 38, 214–220 (1970)Google Scholar
  74. Di Rosa, M., Willoughby, D.A.: Screens for anti-inflammatory drugs. J. Pharm. (Lond.) 23, 297–298 (1971)Google Scholar
  75. Edery, H., Lewis, G.P.: Inhibition of plasma kininase activity at slightly acid pH. Brit. J. Pharmacol. 19, 299–308 (1962)PubMedGoogle Scholar
  76. Edery, H., Lewis, G.P.: Kinin-forming activity and histamine in lymph after tissue injury. J. Physiol. (Lond.) 169, 568–583 (1963)Google Scholar
  77. Ehringer, H., Herzog, P., Konzett, H.: Über die Wirkung von synthetischem Bradykinin auf die Durchblutung der Extremitäten des Menschen. Helv. physiol. pharmacol. Acta 19, C66-C68 (1961)Google Scholar
  78. Eisen, V.: Kinin formation and fibrinolysis in human plasma. J. Physiol. (Lond.) 166, 514–529 (1963)Google Scholar
  79. Eisen, V.: Kinin forming enzymes and substrates in human plasma. J. Physiol. (Lond.) 186, 133P (1966 a)Google Scholar
  80. Eisen, V.: Urates and kinin formation in synovial fluid. Proc. roy. Soc. Med. 59, 302–307 (1966 b)PubMedGoogle Scholar
  81. Eisen, V.: Kinin formation in human diseases. In: Basis Med. Ann. Rev., pp. 146–165. London: Athlone 1969Google Scholar
  82. Eisen, V., Greenbaum, L., Lewis, G.P.: Kinins and anti-inflammatory steroids. Brit. J. Pharmacol. 34, 169–176 (1968)Google Scholar
  83. Eisen, V., Loveday, C.: In vivo effects of cellulose sulphate on plasma kininogen, complement, and inflammation. Brit. J. Pharmacol. 42, 383–391 (1971)Google Scholar
  84. Elliott, D.F., Horton, E.W., Lewis, G.P.: Actions of pure bradykinin. J. Physiol. (Lond.) 153, 473–4480 (1960 b)Google Scholar
  85. Elliott, D.F., Horton, E.W., Lewis, G.P.: The isolation of bradykinin. A plasma kinin from ox blood. Biochem. J. 78, 60–65 (1961)PubMedGoogle Scholar
  86. Elliott, D.F., Lewis, G.P.: Methionyl-lysyl-bradykinin, a new kinin from ox blood. Biochem. J. 95, 437–447 (1965)PubMedGoogle Scholar
  87. Elliott, D. F., Lewis, G.P., Horton, E.W.: The structure of bradykinin—a plasma kinin from ox blood. Biochem. biophys. Res. Commun. 3, 87–91 (1960 a)Google Scholar
  88. Elliott, D.F., Lewis, G.P., Smyth, D.C.: A new kinin from ox blood. Biochem. J. 87, 21P (1963)Google Scholar
  89. Engleman, E.G., Greenbaum, L.M.: Kinin-forming activity of human lymphocytes. Biochem. Pharmacol. 20, 922–924 (1971).PubMedGoogle Scholar
  90. Erdös, E.G.: Enzymes that inactivate active polypeptides. Biochem. Pharmacol. 8, 112 (1961)Google Scholar
  91. Erdös, E.G.: Effect of nonsteroidal anti-inflammatory drugs in endotoxin shock. Biochem. Pharmacol. Suppl., 283–291 (1968)Google Scholar
  92. Erdös, E.G. (Ed.): Bradykinin, Kallidin, and Kallikrein. Handbook of Experimental Pharmacology, Vol. XXV. Berlin-Heidelberg-New York: Springer 1970Google Scholar
  93. Erdös, E.G.: Angiotensin I converting enzyme. Circulat. Res. 36, 247–255 (1975)PubMedGoogle Scholar
  94. Erdös, E.G., Renfrew, A.G., Sloane, E.M., Wohler, J.R.: Enzymatic studies on bradykinin and similar peptides. Ann. N.Y. Acad. Sci. 104, 222–235 (1963 a)Google Scholar
  95. Erdös, E.G., Sloane, E.M.: An enzyme in human blood plasma that inactivates bradykinin and kallidin. Biochem. Pharmacol. 11, 585–592 (1962)PubMedGoogle Scholar
  96. Erdös, E.G., Sloane, E.M., Wohler, I. M.: Carboxypeptidase in blood and other fluids. I. Properties, distribution, and partial purification of the enzyme. Biochem. Pharmacol. 13, 893–905 (1964)Google Scholar
  97. Erdös, E.G., Whohler, J.R., Levine, M.I.: Blocking of the in vivo effects of bradykinin and kallidin with carboxypeptidase B. J. Pharmacol, exp. Ther. 142, 327–334 (1963 b)Google Scholar
  98. Erdös, E.G., Yang, H.Y.T.: Inactivation and potentiation of the effects of bradykinin. In: Erdös, E.G., Back, N., Sicuteri, F. (Eds.): Hypotentive Peptides, pp. 235–251. Berlin-Heidelberg-New York: Springer 1966Google Scholar
  99. Erdös, E.G., Yang, H. Y. T.: An enzyme in microsomal fraction of kidney that inactivates bradykinin. Life Sci. 6, 569–574 (1967 a)PubMedGoogle Scholar
  100. Erdös, E.G., Yang, H.Y.T.: Metabolism of bradykinin and related peptides. In: Rocha e Silva, M., Rothschild, H.A. (Eds.): International Symposium on Vaso-Active Substances: Bradykinin and Related Kinins, pp. 239–246. Sao Paulo: Edart 1967bGoogle Scholar
  101. Erdös, E.G., Yang, H.Y.T.: Kininases. In: Erdös, E.G. (Ed.): Bradykinin, Kallidin, and Kallikrein. Handbook of Experimental Pharmacology, Vol. XXV, pp. 289–323. Berlin-Heidelberg-New York: Springer 1970Google Scholar
  102. Fasciolo, J.C., Halvorsen, K.: Specificity of mammalian kallidinogen. Amer. J. Physiol. 207, 901–905 (1964)PubMedGoogle Scholar
  103. Ferreira, S.H.: A bradykinin-potentiating factor (BPF) present in the venom of Bothrops Jararaca. Brit. J. Pharmacol. 24, 163–169 (1965)PubMedGoogle Scholar
  104. Ferreira, S.H.: Prostaglandins, aspirin-like drugs, and analgesia. Nature (New Biol.) 240, 200–203 (1972)Google Scholar
  105. Ferreira, S.H., Moncada, S., Vane, J.R.: Indomethacin and aspirin abolish prostaglandin release from the spleen. Nature (New Biol.) 231, 237–239 (1971)Google Scholar
  106. Ferreira, S.H., Moncada, S., Vane, J.R.: Prostaglandins and the mechanism of analgesia produced by aspirin-like drugs. Brit. J. Pharmacol. 49, 86–97 (1973)Google Scholar
  107. Ferreira, S.H., Moncada, S., Vane, J.R.: Prostaglandins and signs and symptoms of inflammation. In: Robinson, H.J., Vane, J.R. (Eds.): Prostaglandin Synthetase Inhibitors, pp. 175–187. New York: Raven 1974Google Scholar
  108. Ferreira, S.H., Rocha e Silva, M.: Potentiation of bradykinin by dimercaptopropanol (BAL) and other inhibitors of its destroying enzyme in plasma. Biochem. Pharmacol. 11, 1123–1128 (1962)PubMedGoogle Scholar
  109. Ferreira, S.H., Rocha e Silva, M.: Liberation of bradykinin in the circulating blood of dogs by trypsin, chymotrypsin, and nagarse. Brit. J. Pharmacol. 36, 611–622 (1969)Google Scholar
  110. Ferreira, S.H., Vane, J.R.: The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. Brit. J. Pharmacol. 30, 417–424 (1967 a)PubMedGoogle Scholar
  111. Ferreira, S.H., Vane, J.R.: Half-lives of peptides and amines in the circulation. Nature (Lond.) 215, 1237–1240 (1967 b)Google Scholar
  112. Fiedler, F., Werle, E.: Vorkommen zweier Kallikreinogene im Schweinepankreas und Automation der Kallikrein- und Kallikreinogenbestimmung. Hoppe-Seyler’s Z. physiol. Chem. 348, 1087–1089 (1967)PubMedGoogle Scholar
  113. Forell, M.M.: Therapy with kallikrein and protease inhibitors. Ann. N.Y. Acad. Sci. 104, 368–375 (1963)PubMedGoogle Scholar
  114. Fox, R.H., Goldsmith, R., Kidd, D.J., Lewis, G.P.: Bradykinin as a vasodilator in man. J. Physiol. (Lond.) 157, 589–602 (1961)Google Scholar
  115. Freund, J., Miles, A.A., Mill, P.J., Wilhelm, D.L.: Vascular permeability factors in the secretion of the guinea pig coagulating gland. Nature (Lond.) 182, 174–175 (1958)Google Scholar
  116. Frey, E. K.: Zusammenhänge zwischen Herzarbeit und Nierentätigkeit. Langenbecks Arch. klin. Chir. 142, 663–669 (1926)Google Scholar
  117. Frey, E.K., Kraut, H., Schultz, F.: Über eine nerveninnersekretorische Funktion des Pankreas. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 158, 334–347 (1930)Google Scholar
  118. Frimmer, M.: Beeinflussung der Durchlässigkeit von Blut-Cappilaren der Kaninchenhaut für Makromoleküle durch einige biogene, gefäßaktive Substanzen. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 242, 390–395 (1961)Google Scholar
  119. Fritz, H., Eckert, I., Werle, E.: Isolierung und Charakterisierung von sialinsäurehaltigem und sialinsäurefreiem Kallikrein aus Schweinepankreas. Hoppe-Seyler’s Z. physiol. Chem. 348, 1120–1132 (1967)PubMedGoogle Scholar
  120. Gaddum, J.H., Guth, P.S.: A comparison of the kallikrein-kinin system in sheep and dogs. Brit. J. Pharmacol. 15, 181–184 (1960)PubMedGoogle Scholar
  121. Garcia Leme, J., Hamamura, L.: Formation of a factor increasing vascular permeability during electrical stimulation of the saphenous nerve in rats. Brit. J. Pharmacol. 51, 383–389 (1974)Google Scholar
  122. Garcia Leme, J., Hamamura, L., Leite, M. P., Rochae Silva, M.: Pharmacological analysis of the acute inflammatory process induced in the rat’s paw by local injection of carrageenin and by heating. Brit. J. Pharmacol. 48, 88–96 (1973 b)Google Scholar
  123. Garcia Leme, J., Hamamura, L., Migliorini, R.H., Leite, M.P.: Influence of diabetes upon the inflammatory response of the rat. A pharmacological analysis. Europ. J. Pharmacol. 23, 74–81 (1973 a)Google Scholar
  124. Garcia Leme, J., Hamamura, L., Rocha e Silva, M.: Effect of anti-proteases and hexadimethrine bromide on the release of a bradykinin-like substance during heating (46° C) of rat paws. Brit. J. Pharmacol. 40, 294–309 (1970)Google Scholar
  125. Garcia Leme, J., Rocha e Silva, M.: Competitive and non-competitive inhibition of bradykinin on the guinea-pig ileum. Brit. J. Pharmacol. 25, 50–58 (1965)PubMedGoogle Scholar
  126. Garcia Leme, J., Schapoval, E.E.S., Rocha e Silva, M.: Factors influencing the developement of local swelling induced in the rat’s paw by macromolecular compounds and heating. In: Rocha e Silva, M., Rothschild, H.A. (Eds.): International Symposium on Vaso-Active Polypeptides: Bradykinin and Related Kinins, pp. 213–221. Säo Paulo: Edart 1967Google Scholar
  127. Garcia Leme, J., Walaszek, E.J.: Antagonists of pharmacologically active peptides. Effect on guinea pig ileum and inflammation. In: Proceedings 5 th International Congress Pharmacology, Vol. V, pp. 328–335. Basel-München-Paris-London-New York-Sidney: Karger 1973Google Scholar
  128. Gardner, D.L.: Production of arthritis in the rabbit by the local injection of the mucopolysaccharide caragheenin. Ann. rheum. Dis. 19, 369–376 (1960)PubMedGoogle Scholar
  129. Gardner, D.L.: Pathology of the connective tissue diseases. London: Edward Arnold 1965Google Scholar
  130. Gautvik, K.M., Rugstad, H.D.: Kinin formation and kininogen depletion in rats after intravenous injection of ellagic acid. Brit. J. Pharmacol. 31, 390–400 (1967)PubMedGoogle Scholar
  131. Gilfoil, T.M., Klavins, I.: 5-hydroxytryptamine, bradykinin, and histamine as mediators of inflammatory hyperesthesia. Amer. J. Physiol. 208, 867–876 (1965)PubMedGoogle Scholar
  132. Giordano, F., Scapagnini, U.: L’oedème localisé par bradykinine synthétique chez le rat comme test pour l’évaluation de médicaments anti-inflammatoires. Med. Pharmacol, exp. 17, 445–465 (1967)Google Scholar
  133. Gladner, J.A.: Potentiation of the effect of bradykinin. In: Erdos, E.G., Back, N., Sicuteri, F. (Eds.): Hypotensive Peptides, pp. 344–355. Berlin-Heidelberg-New York: Springer 1966Google Scholar
  134. Gladner, J.A., Murtaugh, P.M., Folk, J.E., Laki, K.: Nature of peptides released by thrombin. Ann. N.Y. Acad. Sci. 104, 47–52 (1963)PubMedGoogle Scholar
  135. Goodwin, L.G., Jones, C.R., Richards, W.H.G., Kohn, J.: Pharmacologically active substances in the urine of burned patients. Brit. J. exp. Path. 44, 551–560 (1963)PubMedGoogle Scholar
  136. Goodwin, L.G., Richards, W.H.G.: Pharmacologically active peptides in the blood and urine of animals infected with Babesia Rodhaini and other pathogenic organisms. Brit. J. Pharmacol. 15, 152–159 (1960)PubMedGoogle Scholar
  137. Graham, R.C., Erbert, R.H., Ratnoff, O.D., Moses, J.M.: Pathogenesis of inflammation. II. In vivo observations of the inflammatory effects of activated Hageman factor and bradykinin. J. exp. Med. 121, 807–818 (1965)PubMedGoogle Scholar
  138. Greaves, M., Schuster, S.: Responses of skin blood vessels to bradykinin, histamine, and 5-hydroxytryptamine. J. Physiol. (Lond.) 193, 255–267 (1967)Google Scholar
  139. Greeff, K., Lühr, R., Strobach, H.: Die Abnahme des Kininogengehaltes des Plasmas beim toxischen, anaphylaktischen und anaphylaktoiden Schock. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 253, 235–239 (1966)Google Scholar
  140. Greenbaum, L.M., Freer, R., Chang, J., Semente, G., Yamafuji, K.: PMN-kinin metabolizing enzymes in normal and malignant leucocytes. Brit. J. Pharmacol. 36, 623–634 (1969)Google Scholar
  141. Greenbaum, L.M., Kim, K.S.: The kinin-forming and kininase activities of rabbit polymorphonuclear leukocytes. Brit. J. Pharmacol. 29, 238–247 (1967)PubMedGoogle Scholar
  142. Greenbaum, L.M., Yamafuji, K.: The in vitro inactivation and formation of plasma kinins by spleen cathepsins. Brit. J. Pharmacol. 27, 230–238 (1966)PubMedGoogle Scholar
  143. Greenbaum, L.M., Yamafuji, K., Kim, K.S.: Studies on the kinin-forming and inactivating enzymes in tissues and leucocytes. In: Rocha e Silva, M., Rothschild, H.A. (Eds.): International Symposium on Vaso-active Polypeptides: Bradykinin and Related Kinins, pp. 21–25. São Paulo: Edart 1967Google Scholar
  144. Greene, L.J., Camargo, A.C.M., Krieger, E.M., Stewart, J.M., Ferreira, S.H.: Inhibition of the conversion of angiotensin I to II and potentiation of bradykinin by small peptides present in Bothropsjararaca venom. Circulat. Res. XXX, Suppl. II, 62–71 (1972)Google Scholar
  145. Guimarães, J.A., Borges, D.R., Prado, E.S., Prado, J.L.: Kinin-converting aminopeptidase from human serum. Biochem. Pharmacol. 22, 3157–3172 (1973)PubMedGoogle Scholar
  146. Guimarães, J.A., Chen-Lu, R., Webster, M.E., Pierce, J.V.: Multiple forms of human plasma kininogen. Fed. Proc. 33, 641 (1974)Google Scholar
  147. Gunnar, R.M., Weeks, R.E.: Effect of tripelennamine hydrochloride on burn shock. Arch. Path. (Chicago) 47, 594–597 (1949)Google Scholar
  148. Guzman, F., Braun, G., Lim, R.K.S.: Visceral pain and the pseudoaffective response to intraarterial injection of bradykinin and other algesic agents. Arch. int. Pharmacodyn. 136, 353–384 (1962)PubMedGoogle Scholar
  149. Guzman, F., Braun, G., Lim, R.K.S., Potter, G.D., Rodgers, D.W.: Narcotic and non-narcotic analgesics which block visceral pain evoked by intraarterial injection of bradykinin and other algesic agents. Arch. int. Pharmacodyn. 149, 571–588 (1964)PubMedGoogle Scholar
  150. Habal, F.M., Burrowes, G.E., Movat, H.Z.: Generation of kinin by plasmin. Fed. Proc. 34, 859 (1975)Google Scholar
  151. Habal, F.M., Movat, H.Z., Burrowes, G.E.: Isolation of two functionally different kininogens from human plasma—separation from proteinase inhibitors and interaction with plasma kallikrein. Biochem. Pharmacol. 23, 2291–2303 (1974)PubMedGoogle Scholar
  152. Haberland, G.L., Rohen, J.W., Eds.: Kininogenases. First Symposium on Physiological Properties and Pharmacological Rational. Stuttgart-New York: F. K. Schattauer 1973Google Scholar
  153. Habermann, E.: Enzymatic kinin release from kininogen and from low-molecular compounds. In: Erdos, E.G., Back, N., Sicuteri, F. (Eds.): Hypertensive Peptides, pp. 116–129. Berlin-Heidelberg-New York: Springer 1966aGoogle Scholar
  154. Habermann, E.: Struktur auf Klärung kininliefernder Peptide aus Rinderserum-Kininogen. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 253, 474–483 (1966 b)Google Scholar
  155. Habermann, E.: Kininogens. In: Erdös, E.G. (Ed.): Bradykinin, Kallidin, and Kallikrein. Handb. Exp. Pharmakol, Vol. XXV, pp. 250–288. Berlin-Heidelberg-New York: Springer 1970Google Scholar
  156. Habermann, E., Blennemann, G.: Ober Substrate und Reaktionsprodukte der kininbildenden Enzyme Trypsin, Serum- und Pankreaskallikrein sowie von Crotalusgift. Naunyn-Schmiedeberg’s Arch. exp. Pathol. Pharmakol. 249, 357–373 (1964)Google Scholar
  157. Habermann, E., Blennemann, G., Müller, B.: Charakterisierung und Reinigung peptischer kininliefernder Fragmente (PKF) sowie von „Pepsitocin“aus Rinderserumkininogen. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 253, 444–463 (1966)Google Scholar
  158. Habermann, E., Helbig, J.: Cleavage of kininogen by cyanogen bromide and enzymes: a procedure for determining position and structure of the kinin-yielding sequence. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 255, 20 (1966)Google Scholar
  159. Habermann, E., Klett, W.: Reinigung und einige Eigenschaften eines Kallikreins auf Schweineserum. Biochem. Z. 346, 133–158 (1966)PubMedGoogle Scholar
  160. Habermann, E., Müller, B.: Zur enzymatischen Spaltung peptischer kininliefernder Fragmente (PKF) sowie von Rinderserumkininogen. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 253, 464–473 (1966)Google Scholar
  161. Hamberg, U.: Plasma protease and kinin release with special reference to plasmin. Ann. N.Y. Acad. Sci. 146, 517–526 (1968)PubMedGoogle Scholar
  162. Hamberg, U., Elg, P., Nissingen, E., Stelwagen, P.: Purification and heterogeneity of human kininogen. Int. J. pept. prot. Res. 7, 261–280 (1975)Google Scholar
  163. Hamberg, U., Rocha e Silva, M.: Studies on the enzymatic inactivation of bradykinin. Acta physiol. scand. 30, 215–225 (1954)PubMedGoogle Scholar
  164. Hamberg, U., Rocha e Silva, M.: On the release of bradykinin by trypsin and snake venom. Arch. int. Pharmacodyn. 110, 222–238 (1957 a)PubMedGoogle Scholar
  165. Hamberg, U., Rocha e Silva, M.: Release of bradykinin as related to the esterase activity of trypsin and the venom of Bothrops jararaca. Experientia (Basel) 13, 489–490 (1957 b)Google Scholar
  166. Harpel, P.C.: Human plasma alpha-2-macroglobulin. An inhibitor of plasma kallikrein. J. exp. Med. 132, 329–352 (1970)PubMedGoogle Scholar
  167. Hathway, W.E., Belhasen, L.P., Hathway, H.S.: Evidence for a new plasma thromboplastin factor. I. Case report, coagulation studies and physicochemical properties. Blood 26, 521–532 (1965)Google Scholar
  168. Hebborn, P., Shaw, B.: The action of sodium salicylate and aspirin on some kallikrein systems. Brit. J. Pharmacol. 20, 254–263 (1963)PubMedGoogle Scholar
  169. Henriques, O.B., Fichman, M., Beraldo, W.T.: Bradykinin-releasing factor from Bothrops jararaca venom. Nature (Lond.) 187, 414–415 (1960)Google Scholar
  170. Henriques, O.B., Kauritcheva, N., Kuznetsova, V., Astrakan, M.: Substrates of kinin-releasing enzymes isolated from horse plasma. Nature (Lond.) 215, 1200–1201 (1967)Google Scholar
  171. Henriques, O.B., Lavras, A.A.C., Fichman, M., Picarelli, Z.P.: Plasma enzymes that release kinins. Biochem. Pharmacol. 15, 31–40 (1966)PubMedGoogle Scholar
  172. Herxheimer, H., Streseman, E.: Bradykinin and ethanol in bronchial asthma. Arch. int. Pharmacodyn. 144, 315–318 (1963)PubMedGoogle Scholar
  173. Hilton, S.M.: Plasma kinin and blood flow. In: Schachter, M. (Ed.): Polypeptides Which Affect Smooth Muscles and Blood Vessels, pp. 258–265. Oxford: Pergamon 1960Google Scholar
  174. Hilton, S.M., Lewis, G.P.: The relationships between glandular activity, bradykinin formation and functional vasodilatation in the submandibular salivary gland. J. Physiol. (Lond.) 134, 471–478 (1956)Google Scholar
  175. Hladovéc J., Mansfeld, V., Horáková, Z.: Inhibitory action of trypsin and trypsin-inhibitors on experimental inflammation in rats. Experientia (Basel) 14, 146–147 (1958)Google Scholar
  176. Hochstrasser, K., Werle, E.: Über kininliefernde Peptide aus pepsinverdautem Rinderplasmaprotein. Hoppe-Syler’s Z. physiol. Chem. 348, 177–182 (1967)Google Scholar
  177. Hori, S.: The presence of bradykinin-like polypeptides, kinin-releasing and—destroying activity in braiN.JaP.J. Physiol. 18, 772–787 (1968)Google Scholar
  178. Horton, E.W.: The estimation of urinary kallikrein. J. Physiol. (Lond.) 148, 267–282 (1959).Google Scholar
  179. Hureau, J., Forlot, P., Raby, C., Vairel, E.: Évidence de la présence de trypsine dans le sang périphérique au cours des pancréatites aiguës hemorrhagiques. Son rôle dans le dévelopment du choc. Rev. franç. Êt. clin. biol. 13, 80–82 (1968)Google Scholar
  180. Innerfield, I.: The anti-inflammatory effect of parenterally administered proteases. Ann. N.Y. Acad. Sci. 68, 167–177 (1957)PubMedGoogle Scholar
  181. Innerfield, I., Bundy, R.E., Hochberg, R.: Bradykinin antagonism following oral protease therapy. Proc. Soc. exp. Biol. (N.Y.) 112, 295–297 (1963)Google Scholar
  182. Inoki, R., Toyoda, T., Yamamoto, I.: Elaboration of a bradykinin-like substance in dog’s canine pulp during electrical stimulation and its inhibition by narcotic and nonnarcotic analgesics. Naunyn-Schmiedeberg’s Arch. Pharmacol. 279, 387–398 (1973)Google Scholar
  183. Jacobsen, S.: Substrates for plasma kinin-forming enzymes in human, dog, and rabbit plasmas. Brit. J. Pharmacol. 289, 64–72 (1966 a)Google Scholar
  184. Jacobsen, S.: Observations on the content of kininogen, kallikrein, and kininase in lymph from hind limbs of dogs and rabbits. Brit. J. Pharmacol. 27, 213–221 (1966b)PubMedGoogle Scholar
  185. Jacobsen, S., Kriz, M.: Some data on two purified kininogens from human plasma. Brit. J. Pharmacol. 29, 25–36 (1967)PubMedGoogle Scholar
  186. Jacobsen, S., Waaler, B. A.: The effect of scalding on the content of kininogen and kininase in limb lymph. Brit. J. Pharmacol. 27, 222–229 (1966)PubMedGoogle Scholar
  187. Jancsó, N., Jancsó-Gábor, A., Szolcsányi, J.: Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Brit. J. Pharmacol. 31, 138–151 (1967)PubMedGoogle Scholar
  188. Juan, H., Lembeck, F.: Action of peptides and other algesic agents on paravascular pain receptors of the isolated perfused rabbit ear. Naunyn-Schmiedeberg’s Arch. Pharmacol. 283, 151–164 (1974)Google Scholar
  189. Kaller, H., Hoffmeister, F., Kroneberg, G.: Die Wirkung von Trasylol auf verschiedene Ödemformen der Rattenpfote. Arch. int. Pharmacodyn. 161, 398–409 (1966)PubMedGoogle Scholar
  190. Kaplan, A.P., Austen, K.F.: A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J. exp. Med. 133, 696–712 (1971)PubMedGoogle Scholar
  191. Kaplan, A.P., Kay, A.B., Austen, K.F.: A prealbumin activator of prekallikrein. III. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J. exp. Med. 135, 81–97 (1972)PubMedGoogle Scholar
  192. Keele, C.A.: Clinical and pathological aspects of kinins in man. Proc. roy. Soc. B, 173, 361–369 (1969)Google Scholar
  193. Keele, C.A., Armstrong, D.: Substances producing pain and itch. London: Edward Arnold Ltd. 1964Google Scholar
  194. Kellermeyer, R.W.: Inflammatory process in acute gouty arthritis. III. Vascular permeability-enhancing activity in normal human synovial fluid; induction by Hageman factor activators; and inhibition by Hageman factor antiserum. J. Lab. clin. Med. 70, 372–383 (1967)PubMedGoogle Scholar
  195. Kellermeyer, R.W., Breckenridge, R.T.: The inflammatory process in acute gouty arthritis. I. Activation of Hageman factor by sodium urate crystals. J. Lab. clin. Med. 65, 307–315 (1965)PubMedGoogle Scholar
  196. Kellermeyer, R.W., Breckenridge, R.T.: The inflammatory process in acute gouty arthritis. II. The presence of Hageman factor and plasma thromboplastin antecedent in synovial fluid. J. Lab. clin. Med. 67, 455–460 (1966)PubMedGoogle Scholar
  197. Kellett, D.N.: On the anti-inflammatory activity of protamine sulphate and of hexadimethrine bromide, inhibitors of plasma kinin formation. Brit. J. Pharmacol. 24, 705–713 (1965)PubMedGoogle Scholar
  198. Kellett, D.N.: On the mechanism of the anti-inflammatory activity of hexadimethrine bromide. Brit. J. Pharmacol. 26, 351–357 (1966)PubMedGoogle Scholar
  199. Komiya, M., Kato, H., Suzuki, T.: Bovine plasma kininogens. I. Further purification of high molecular weight kininogen and its physic-chemical properties. J. Biochem. (Tokyo) 76, 811–822 (1974)Google Scholar
  200. Konzett, H.: Some properties of synthetic bradykinin-like polypeptides. Biochem. Pharmacol. 10, 39–45 (1962)Google Scholar
  201. Konzett, H., Stürmer, E.: Synthetic bradykinin: its biological identity with natural pure trypsin bradykinin. Nature (Lond.) 188, 998 (1960)Google Scholar
  202. Kraut, H., Frey, E. K., Werle, E.: Über den Nachweis und das Vorkommen des Kallikreins in Blut. VIII. Mitteilung über Kallikrein. Hoppe-Seyler’s Z. physiol. Chem. 222, 73–99 (1933)Google Scholar
  203. Kraut, H., Frey, E.K., Werle, E., Schultz, F.: Nachweis und Vorkommen des Kallikreins in Harn. IX. Mitteilung über Kallikrein. Hoppe-Seyler’s Z. physiol. Chem. 230, 259–277 (1934)Google Scholar
  204. Lahiri, B., Rosenberg, R., Talamo, R.C., Mitchell, B., Bagdasarian, A., Colman, R.W.: Antithrombin III, an inhibitor of human plasma kallikrein. Fed. Proc. 33, 642 (1974)Google Scholar
  205. Lecomte, J.: Bradykinine et réactions anaphylactiques du lapin. C.R. Soc. Biol. (Paris) 154, 1118–1120 (1960a)Google Scholar
  206. Lecomte, J.: Antagonisme entre bradykinin synthétique et phénylbutazone chez le lapin. C.R. Soc. Biol. (Paris) 154, 2389–2391 (1960 b)Google Scholar
  207. Lecomte, J.: Consommation des kininogènes plasmatiques an cours du choc anaphylactique du lapin. C.R. Soc. Biol. (Paris) 155, 1411–1413 (1961)Google Scholar
  208. Lecomte, J., Damas, J.: Formation de kinines in vivo lors de l’administration de sulfate de dextran chez le rat. C.R. Soc. Biol. (Paris) 162, 2055–2057 (1968)Google Scholar
  209. Lecomte, J., Petit, J.M., Mélon, J., Troquet, J., Marcelle, R.: Proprietés broncho-constrictrices de la bradykinine chez l’homme asthmatique. Arch. int. Pharmacodyn. 137, 232–235 (1962)Google Scholar
  210. Lecomte, J., Troquet, J.: Antagonisms entre bradykinine et phénylbutazone chez le lapin. C.R. Soc. Biol. (Paris) 154, 1115–1117 (1960)Google Scholar
  211. Lembeck, F., Juan, H.: Interaction of prostaglandins and indomethacin with algesic substances. Naunyn-Schmiedeberg’s Arch. Pharmacol. 285, 301–313 (1974)Google Scholar
  212. Lewis, G.P.: Formation of plasma kinins by plasmin. J. Physiol. (Lond.) 140, 285–300 (1958)Google Scholar
  213. Lewis, G.P.: Active polypeptides derived from plasma proteins. Physiol. Rev. 40, 647–676 (1960)PubMedGoogle Scholar
  214. Lewis, G.P.: Bradykinin-biochemistry, pharmacology, and its physiological role in controlling local blood flow. Sci. Basis Med. 14, 242–258 (1962)Google Scholar
  215. Lewis, G.P.: Kinins in inflammation and tissue injury. In: Erdos, E.G. (Ed.): Bradykinin, Kallidin, and Kallikrein, Handb. exp. Pharmakol., Vol. XXV, pp. 516–530. Berlin-Heidelberg-New York: Springer 1970Google Scholar
  216. Lewis, G.P., Wawretscheck, W.A.: Effect of thermal injury on the kinin system in rabbit hind limb lymph. Brit. J. Pharmacol. 43, 127–139 (1971)Google Scholar
  217. Lewis, G.P., Work, T.: Formation of bradykinin or bradykinin-like substances by the action of plasmin on plasma proteins. J. Physiol. (Lond.) 135, 7 P (1956)Google Scholar
  218. Lewis, T.: The blood vessels of the human skin and their responses. London: Shaw & Sons Ltd. 1927Google Scholar
  219. Lim, R.K.S.: Neuropharmacology of pain and analgesia. In: Lim, R.K.S., Armstrong, D., Pardo, E.G. (Eds.): Pharmacology of Pain, pp. 169–217. Oxford: Pergamon Press 1968Google Scholar
  220. Lim, R.K.S., Guzman, F., Rodgers, D.W., Gotto, K., Braun, C., Dickerson, G.D., Engle, R.J.: Site of action of narcotic and non-narcotic analgesics determined by blocking bradykinin evoked visceral pain. Arch. int. Pharmacodyn. 152, 25–58 (1964)PubMedGoogle Scholar
  221. Lima, A.O.: Pharmacologically active substances released during anaphylactic shock in the mouse. Int. Arch. Allergy 32, 46–54 (1967)PubMedGoogle Scholar
  222. Lish, P.M., McKinney, G.R.: Pharmacology of methdilazine. II. Some determinants and limits of action on vascular permeability and inflammation in model systems. J. Lab. clin. Med. 61, 1015–1027 (1963)Google Scholar
  223. Löbbecke, E.A.: Effect of kallikrein on the proliferation of various cell systems. In: Haberland, G.L., Rohen, J.W. (Eds.): Kininogenases. First Symp. on Physiological Properties and Pharmacological Rational, pp. 161–169. Stuttgart-New York: F. K. Schattauer 1973Google Scholar
  224. McCarthy, D.A., Potter, D.E., Nicolaides, E.D.: An in vivo estimation of the potencies and half-lives of synthetic bradykinin and kallidin. J. Pharmacol, exp. Ther. 148, 117–122 (1965)Google Scholar
  225. McCarty, D.J., Jr.: Cristal-induced inflammation of the joints. Ann. Rev. Med. 21, 357–366 (1970)PubMedGoogle Scholar
  226. McConnell, D.J.: Inhibitors of kallikrein in human plasma. J. clin. Invest. 51, 1611–1623 (1972)PubMedGoogle Scholar
  227. McGiff, J.C., Terragno, A.M., Malik, K.U., Lonigro, A.J.: Release of a prostaglandin E-like substance from canine kidney by bradykinin. Circulat. Res. 31, 36–43 (1972)PubMedGoogle Scholar
  228. McKay, D.G., Lactour, J.G., Parrish, M.H.: Activation of Hageman factor by alpha-adrenergic stimulation. Thrombos. Diathes. haemorrh. (Stuttg.) 23, 417–422 (1970)Google Scholar
  229. Majno, G.: Mechanisms of abnormal vascular permeability in acute inflammation. In: Thomas L., Uhr, J.W., Grant, L. (Eds.): Injury, Inflammation, and Immunity, pp. 58–93. Baltimore: The Williams & Wilkins Company 1964Google Scholar
  230. Majno, G., Palade, G.E.: Studies on inflammation. I. The effect of histamine and serotonin on vascular permeability: An electron microscopic study. J. biophys. biochem. Cytol. 11, 571–605 (1961)PubMedGoogle Scholar
  231. Maling, H.M., Webster, M.E., Williams, M.A., Saul, W., Anderson, Jr., W.: Inflammation induced by histamine, serotonin, bradykinin, and compound 48/80 in the rat: antagonists and mechanisms of action. J. Pharmacol, exp. Ther. 191, 300–310 (1974)Google Scholar
  232. Margolis, J.: Initiation of blood coagulation by glass and related surfaces. J. Physiol. (Lond.) 137, 95–109 (1957)Google Scholar
  233. Margolis, J.: Activation of plasma by contact with glass. Evidence for a common reaction which releases plasma-kinin and initiates coagulation. J. Physiol. (Lond.) 144, 1–22 (1958)Google Scholar
  234. Margolis, J.: The mode of action of Hageman factor in the release of plasma kinin. J. Physiol. (Lond.) 151, 238–252 (1960)Google Scholar
  235. Margolis, J.: Activation of Hageman factor by saturated fatty acids. Aust. J. exp. Biol. med. Sci. 40, 505–513 (1962)PubMedGoogle Scholar
  236. Margolis, J., Bishop, E.A.: Interrelations between different mechanisms of release of biologically active peptides from blood plasma. Nature (Lond.) 194, 749–751 (1962)Google Scholar
  237. Margolis, J., Bishop, E.: Studies on plasma kinins. I. The composition of kininogen complex. Aust. J. exp. Biol. med. Sci. 41, 293–306 (1963)PubMedGoogle Scholar
  238. Margolis, J., Bruce, S., Starzecki, B., Horner, G.J., Halmagyi, D.F.J.: Release of bradykinin-like substance (BKLS) in sheep by venom of Crotalus atrox. Aust. J. exp. Biol. med. Sci. 43, 237–244 (1965)PubMedGoogle Scholar
  239. Mason, D.T., Melmon, K.L.: Effects of bradykinin in forearm venous tone and vascular resistance in man. Circulat. Res. 17, 106–113 (1965)PubMedGoogle Scholar
  240. Melmon, K.L., Cline, M.J.: Kallikrein activator and kininase in human granulocytes: a model of inflammation. In: Rocha e Silva, M., Rothschild, H.A. (Eds.): Int. Symp. on Vaso-active kinins: Bradykinin and Related Kinins, pp. 223–228. São Paulo: Edart 1967Google Scholar
  241. Melmon, K.L., Cline, M.J.: The interaction of leucocytes on the kinin system. Biochem. Pharmacol. Suppl., 271–281 (1968)Google Scholar
  242. Melmon, K.L., Webster, M.E., Goldfinger, S.E., Seegmiller J.E.: The presence of a kinin in inflammatory synovial effusion from arthritides of varying etiologies. Arthr. Rheum. 10, 13–20 (1967)Google Scholar
  243. Merrifield, R.H.: Solid-phase peptide synthesis. IV. The synthesis of methionyl-lysyl-bradykinin. J. org. Chem. 29, 3100–3102 (1964)Google Scholar
  244. Miles, A.A.: Large molecular substances as mediators of the inflammatory reaction. Ann. N.Y. Acad. Sci. 116, 855–865 (1964)PubMedGoogle Scholar
  245. Miles, A.A., Miles, E.M.: Vascular reactions to histamine-liberator and leukotaxine in the skin of guineapigs. J. Physiol. (Lond.) 118, 228–257 (1952)Google Scholar
  246. Miles, A.A., Wilhelm, D.L.: The activation of endogenous substances inducing pathological increases of capillary permeability. In: Stoner, H.B. (Ed.): The Biochemical Response to Injury, pp. 51–79. Oxford: Blackwell 1960Google Scholar
  247. Miller, R.L., Webster, M.E., Melmon, K.L.: Interaction of leukocytes and endotoxin with the plasmin and kinin systems. Europ. J. Pharmacol. 33, 53–60 (1975)Google Scholar
  248. Moncada, S., Ferreira, S.H., Vane, J.R.: Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature (Lond.) 246, 217–219 (1973)Google Scholar
  249. Morgan, A., Robinson, L.A., White, T.T.: Postoperative changes in the trypsin inhibitor activities of human pancreatic juice and the influence of infusion of trasylol on the inhibitor activity. Amer. J. Surg. 115, 131–135 (1968)PubMedGoogle Scholar
  250. Mörsdorf, K.: The inhibition of protein catabolism by anti-inflammatory drugs. In: Bertelli, A., Houck, J.C. (Eds.): Inflammation Biochemistry and Drug Interaction, pp. 255–260. Amsterdam: Excerpta Medica 1969Google Scholar
  251. Mörsdorf, K., Marten, S., Purchert, J.: Ein Beitrag zur antiproteolytischen Wirkungsqualität von Phenylbutazon, Oxyphenbutazon und Natriumsalicylat. Arzneimittel-Forsch. 18, 1516–1520 (1968)Google Scholar
  252. Movat, H.Z.: Activation of the kinin system by antigen-antibody complexes. In: Rocha e Silva, M., Rothschild, H.A. (Eds.): Int. Symp. on Vaso-Active Polypeptides: Bradykinin and Related kinins, pp. 177–188. São Paulo: Edart 1967Google Scholar
  253. Nicolaides, E.D., De Wald, H.A., McCarthy, D.S.: The synthesis of a biologically active decapeptide having the structure proposed for kallidin II. Biochem. biophys. Res. Commun. 6, 210–212 (1961)PubMedGoogle Scholar
  254. Nicolaides, E.D., De Wald, H.A., McCarthy, D.A.: The synthesis of kinin analogs. Ann. N.Y. Acad. Sci. 104, 15–23 (1963)PubMedGoogle Scholar
  255. Northover, B.J., Subramanian, G.: Analgesic-antipyretic drugs as inhibitors of kallikrein. Brit. J. Pharmacol. 17, 107–115 (1961)PubMedGoogle Scholar
  256. Nugent, F.W., Zuberi, S., Bulan, M.B.: Kinin precurssor in experimental pancreatitis. Proc. Soc. exp. Biol. (N.Y.) 130, 566–567 (1969)Google Scholar
  257. Onabanjo, A.O., Bhabani, A.R., Maegraith, B.G.: The significance of kinin-destroying enzymes activity in Plasmodium knowlesi malarial infection. Brit. J. exp. Path. 51, 534–540 (1970)PubMedGoogle Scholar
  258. Onabanjo, A.O., Maegraith, B.G.: Kallikrein as a pathogenic agent in Plasmodium knowlesi infection in Macaca mulatta. Brit. J. exp. Path. 51, 523–533 (1970)PubMedGoogle Scholar
  259. Oshima, G., Kato, J., Erdos, E.G.: Subunits of human plasma carboxypeptidase N (Kininase I; anaphylatoxin inactivator). Biochem. biophys. Acta. 365, 344–348 (1974)Google Scholar
  260. Oshima, G., Sato-Omori, T., Suzuki, T.: Distribution of proteinase, arginine-ester hydrolase and kinin releasing enzyme in various kinds of snake venoms. Toxicon 7, 229–234 (1969)PubMedGoogle Scholar
  261. Özge-Anwar, A.H., Movat, H.Z., Scott, J.G.: The kinin system of human plasma. IV. The interrelationship between the contact phase of blood coagulation and the plasma kinin system in man. Thrombos. Diathes. haemorrh. (Stuttg.) 27, 141–158 (1972)Google Scholar
  262. Parrat, J.R., West, G.B.: 5-hydroxytryptamine and the anaphylactoid reaction in the rat. J. Physiol. (Lond.) 139, 27–41 (1957)Google Scholar
  263. Pela, I.R., Gardey-Levassort, C., Lechat, P., Rocha e Silva, M.: Brain kinins and fever induced by bacterial pyrogens in rabbits. J. Pharm. (Lond.) 27, 793–794 (1975)Google Scholar
  264. Perris, A.D., Whitfield, J.F.: The mitogenic action of bradykinin on thymic lymphocytes and its dependence on calcium. Proc. Soc. exp. Biol. (N.Y.) 130, 1198–1201 (1969)Google Scholar
  265. Phelps, P., McCarty, D.J., Jr.: Crystal-induced inflammation in canine joints. II. Importance of polymorphonuclear leukocytes. J. exp. Med. 124, 115–126 (1966)PubMedGoogle Scholar
  266. Phelps, P., Prockop, D.J., McCarty, D.J.: Crystal induced inflammation in caninine joints. III. Evidence against bradykinin as a mediator of inflammation. J. Lab. clin. Med. 68, 433–444 (1966)PubMedGoogle Scholar
  267. Pierce, J.V.: Structural features of plasma kinins and kininogens. Fed. Proc. 27, 52–57 (1968)PubMedGoogle Scholar
  268. Pierce, J.V.: Purification of mammalian kallikrein, kininogens, and kinins. In: Erdos, E.G. (Ed.): Bradykinin, Kallidin, and Kallikrein, Hand. exp. Pharmak., Vol. XXV, pp. 21–51. Berlin-Heidelberg-New York: Springer 1970Google Scholar
  269. Pierce, J.V., Webster, M.E.: Human plasma kallidins; isolation and chemical studies. Biochem. biophys. Res. Commun. 5, 353–357 (1961)Google Scholar
  270. Pierce, J.V., Webster, M.E.: The purification and some properties of two different kallidinogens from human plasma. In: Erdos, E.G., Back, N., Sicuteri, F. (Eds.): Hypotensive Peptides, pp. 130–138. Berlin-Heidelberg-New York: Springer 1966Google Scholar
  271. Piper, P.J., Vane, J.R.: Release of aditional factors in anaphylaxis and its antagonism by antiinflammatory drugs. Nature (Lond.) 223, 20–35 (1969)Google Scholar
  272. Pisano, J.J.: Chemistry and biology of the kallikreins-kinin system. In: Reich, E., Rifkin, D.B., Shaw, E. (Eds.): Proteases and Biological Control, pp.199–222. Cold Spring Harbor Laboratory 1975Google Scholar
  273. Pisano, J.J., Austen, K.F. (Eds.): Chemistry and biology of the kallikrein-kinin system in health and disease. Fogarty Int. Center Proc. 27. Washington, D.C.: U.S. Gov. Printing Office 1977Google Scholar
  274. Pless, J., Stürmer, E., Gutmann, S., Boissonnas, R.A.: Kallidin, Synthese und Eigenschaften. Helv. chim. Acta 45, 394–396 (1962)Google Scholar
  275. Popieraitis, A.A., Thompson, A.G.: The site of bradykinin release in acute experimental pancreatitis. Arch. Surg. (Chicago) 98, 73–77 (1969)Google Scholar
  276. Powers, S.R., Brown, H.H., Stein, A.: The pathogenesis of acute and chronic pancreatitis. Ann. Surg. 142, 690–697 (1955)PubMedGoogle Scholar
  277. Prado, J.L.: Proteolytic enzymes as kininogenases. In: Erdos, E.G. (Ed.): Bradykinin, Kallidin, and Kallikreins. Handb. exp. Pharmakol., pp. 156–192. Berlin-Heidelberg-New York: Springer 1970Google Scholar
  278. Prado, J.L., Limãos, E.A., Roblero, J., Freitas, J.O., Prado, E.S., Paiva, A.C.M.: Recovery and conversion of kinins in exsanguinated rat preparations. Naunyn-Schmiedeberg’s Arch. Pharmacol. 290, 191–205 (1975)Google Scholar
  279. Prado, J.L., Mendes, J., Rosa, R.C.: On the kininogenic activity of ficin, with a note on papain. An. Acad. bras. Cienc. 37, 295–301 (1965)Google Scholar
  280. Prado, J.L., Monier, R., Prado, E.S., Fromageot, C.: Pharmacologically active polypeptide formed from blood globulin by a cysteine-activated protease from Clostridium histolyticum. Biochim. biophys. Acta 22, 87–95 (1956)PubMedGoogle Scholar
  281. Ratnoff, O.D., Miles, A.A.: The induction of permeability-increasing activity in human plasma by activated Hageman factor. Brit. J. exp. Path. 45, 328–345 (1964)PubMedGoogle Scholar
  282. Ratnoff, O.D., Pensky, J., Ogston, D., Naff, G.B.: The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the Clr subcomponent of the first component of complement by serum C′1 esterase inhibitor. J. exp. Med. 129, 315–332 (1969)PubMedGoogle Scholar
  283. Reis, M.L., Medeiros, M.C., Rocha e Silva, M.: Release and destruction of kinins by a proteolytic enzyme (Pronase) derived from a fungus Streptomyces griseus. In: Abstracts III International Pharmacology Congress. São Paulo: Abs. 485, 1966Google Scholar
  284. Reis, M.L., Okino, L., Rocha e Silva, M.: Comparative pharmacological actions of bradykinin and related kinins of larger molecular weights. Biochem. Pharmacol. 20, 2935–2946 (1971)PubMedGoogle Scholar
  285. Richards, W.H.G.: Pharmacologically active substances in the blood and urine of mice infected with Trypanosoma brucei. Brit. J. Pharmacol. 24, 124–131 (1965)PubMedGoogle Scholar
  286. Rixon, R.H., Whitfield, J.F.: Kallikrein, kinin, and cell proliferation. In: Haberland, G.L., Roten, J.W. (Eds.): Kininogenases, First Symposium on Physiological Properties and Pharmacological Rational, pp. 131–145. Stuttgart-New York: F. K. Schattauer 1973Google Scholar
  287. Rixon, R.H., Whitfield, J. F., Bayliss, J.: The stimulation of mitotic activity in the thymus and bone marrow of rats by kallikrein. Horm. Metab. Res. 3, 279–284 (1971)PubMedGoogle Scholar
  288. Rocha e Silva, M.: Bradykinin-mechanism of its release by trypsin and kallikrein. Arch. int. Pharmacodyn. 88, 271–282 (1951)Google Scholar
  289. Rocha e Silva, M.: On the participation of polypeptides and biogenic amines in the acute inflammatory reactions. In: Jasmin, G. (Ed.): Endocrine Aspects of Disease Processes, pp. 74–95. St. Louis: Warren H. Green, Inc. 1968Google Scholar
  290. Rocha e Silva, M.: Kinin Hormones. Springfield: Charles C. Thomas 1970Google Scholar
  291. Rocha e Silva, M., Antonio, A.: Release of bradykinin and the mechanism of production of a “thermic edema (45° C)” in the rat. Med exp. 3, 371–382 (1960)PubMedGoogle Scholar
  292. Rocha e Silva, M., Beraldo, W.T., Rosenfeld, G.: Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Amer. J. Physiol. 156, 261–273 (1949)PubMedGoogle Scholar
  293. Rocha e Silva, M., Cavalcanti, R.Q., Reis, M.L.: Anti-inflammatory actions of sulfated polysaccharides. Biochem. Pharmacol. 18, 1285–1295 (1969)PubMedGoogle Scholar
  294. Rocha e Silva, M., Garcia Lerne, J.: Studies on the antagonists of bradykinin. In: Garattini, S., Dukes, M.N.G. (Eds.): Non steroidal anti-inflammatory drugs, pp. 120–133. Amsterdam: Excerpta Medica 1965Google Scholar
  295. Rocha e Silva, M., Garcia Lerne, J.: Chemical mediators of the acute inflammatory reaction. Oxford: Pergamon 1972Google Scholar
  296. Rocha e Silva, M., Reis, M.L., Ferreira, S.H.: Release of kinins from fresh plasma under varying experimental conditions. Biochem. Pharmacol. 16, 1665–1676 (1967)PubMedGoogle Scholar
  297. Rocha e Silva, M., Rosenthal, S.R.: Release of pharmacologically active substances from the rat skin in vivo following thermal injury. J. Pharmacol, exp. Ther. 132, 110–116 (1961)Google Scholar
  298. Rogers, D.E.: Intracellular inflammation: dynamics and metabolic changes in polymorphonuclear leukocytes participating in phagocytosis. In: Thomas, L., Uhr, J.W., Grant, L. (Eds.): Injury, Inflammation, and Immunity, pp. 110–126. Baltimore: Williams & Wilkins Comp. 1964Google Scholar
  299. Rohen, J.W., Peterhoff, I.: Stimulation of mitotic activity by kallikrein in the gastrointestinal tract of rats. In: Haberland, G.L., Rohen, J.W. (Eds.): Kininogenases. First Symp. on Physiological Properties and Pharmacological Rational, pp. 147–157. Stuttgart-New York: F. K. Schattauer 1973Google Scholar
  300. Rosa, A.T., Rothschild, Z., Rothschild, A.M.: Fibrinolytic activity evoked in the plasma of the normal and adrenalectomized rat by cellulose sulfate. Brit. J. Pharmacol. 45, 470–475 (1972)Google Scholar
  301. Rosenthal, S.R., Minard, D.: Experiments on histamine as the chemical mediator for cutaneous pain. J. exp. Med. 70, 415–425 (1939)PubMedGoogle Scholar
  302. Rothschild, A.M.: Pharmacodynamic properties of cellulose sulfate and related polysaccharides—a group of bradykinin-releasing compounds. In: Rocha e Silva, M., Rothschild, H.A. (Eds.): Int. Symp. on Vaso-Active Polypeptides: Bradykinin and Related Kinins, pp. 197–203. São Paulo: Edart 1967Google Scholar
  303. Rothschild, A.M.: Some pharmacodynamic properties of cellulose sulfate, a kininogen-depleting agent in the rat. Brit. J. Pharmacol. 33, 501–512 (1968 a)PubMedGoogle Scholar
  304. Rothschild, A.M.: Role of anaphylatoxin and of bradykinin in passive cutaneous anaphylaxis against heterologous precipitating antibody in the rat. In: Schild, H.O. (Ed.): Immunophar-macology, pp. 83–89. Oxford: Pergamon 1968bGoogle Scholar
  305. Rothschild, A.M., Castania, A.: Endotoxin shock in dogs pretreated with cellulose sulfate, an agent causing partial plasma kininogen depletion. J. Pharm. (Lond.) 20, 77–78 (1968)Google Scholar
  306. Rothschild, A.M., Castania, A., Cordeiro, R.S.B.: Consumption of kininogen, formation of kinin and activation of arginine ester hydrolase in rat plasma by rat peritoneal fluid cells in the presence of 1-adrenaline. Naunyn-Schmiedeberg’s Arch. Pharmacol. 285, 243–256 (1974a)Google Scholar
  307. Rothschild, A.M., Cordeiro, R.S.B., Castania, A.: Lowering of kininogen in rat blood by catecholamines. Involvement of non-eosinophil granulocytes and selective inhibition by trasylol. Naunyn-Schmiedebergs Arch. Pharmacol. 282, 323–326 (1974 b)PubMedGoogle Scholar
  308. Rothschild, A.M., Gascon, L.A.: Effect of agar on bradykininogen levels and esterolytic activity in rat plasma. Experientia (Basel) 21, 208–209 (1965)Google Scholar
  309. Rothschild, A.M., Gascon, L.A.: Sulphuric esters of polysaccharides as activators of a bradykinin-forming system in plasma. Nature (Lond.) 212, 1364 (1966)Google Scholar
  310. Rothschild, Z., Rosa, A.T., Rothschild, A.M.: On a plasminogen activator induced in rat plasma by cellulose sulfate, an activator of the kinin-generating system. Acta physiol. lat.-amer. 18, 199 (1968)Google Scholar
  311. Rugstad, H.E.: Kininase production by some microbes. Brit. J. Pharmacol. 28, 315–323 (1966)PubMedGoogle Scholar
  312. Ryan, J.W., Moffat, J.G., Thompson, A.G.: Role of bradykinin in the development of acute pancreatitis. Nature (Lond.) 204, 1212–1213 (1964)Google Scholar
  313. Ryan, J.W., Moffat, J.G., Thompson, A.G.: Role of bradykinin system in acute hemorrhagic pancreatitis. Arch. Surg. (Chicago) 91, 14–24 (1965)Google Scholar
  314. Ryan, J.W., Roblero, J., Stewart, J.M.: Inactivation of bradykinin in the pulmonary circulation. Biochem. J. 110, 795–797 (1968)PubMedGoogle Scholar
  315. Ryan, J.W., Rocha e Silva, M.: Release of kinins by acidified bovine Pseudoglobulin. Biochem. Pharmacol. 20, 459–462 (1971)PubMedGoogle Scholar
  316. Sampaio, M.U., Reis, M.L., Fink, E., Camargo, A.C.M., Greene, L.J.: Chromatographic systems for desalting and separating kinins: application to trypsin-treated human plasma. Life Sci. 16, 796 (1975)Google Scholar
  317. Sampaio, C., Wong, S.C., Show, E.: Human plasma kallikrein. Arch. Biochem. 165, 133–139 (1974)PubMedGoogle Scholar
  318. Sander, G.E., Huggins, C.G.: Vasoactive peptides. Ann. Rev. Pharmacol. 12, 227–264 (1972)PubMedGoogle Scholar
  319. Satake, K., Rozmanith, J.S., Appert, H., Howard, J.M.: Hemodynamic change and bradykinin levels in plasma and lymph during experimental acute pancreatites in dogs. Ann. Surg. 178, 659–662 (1973)PubMedGoogle Scholar
  320. Schachter, M.: A delayed slow contracting effect of serum and plasma due to the release of a substance resembling kallidin and bradykinin. Brit. J. Pharmacol. 11, 111–118 (1956)PubMedGoogle Scholar
  321. Schiller, W.R., Suriyapa, C., Anderson, M.C.: A review of experimental pancreatitis. J. surg. Res. 16, 69–90 (1974)PubMedGoogle Scholar
  322. Schröder, E.: Über Peptidsynthesen. Synthese von Methionyl-Lysyl-Bradykinin, einem Kinin aus Rinderblut. Experientia (Basel) 20, 39 (1964)Google Scholar
  323. Schröder, E.: Structure-activity relationships of kinins. In: Erdös, E.G. (Ed.): Bradykinin, Kallidin, and Kallikrein. Handb. exp. Pharmakol., Vol. XXV, pp. 324–350. Berlin-Heidelberg-New York: Springer 1970Google Scholar
  324. Schröder, E., Lübke, K.: The peptides, Vol. II. New York-London: Academic Press 1966Google Scholar
  325. Schwab, J.: Kininases in leucocytes and other tissues. Nature (Lond.) 195, 345–347 (1962)Google Scholar
  326. Sevitt, S.: Inflammatory changes in burned skin: Reversible and irreversible effects and their pathogenesis. In: Thomas, L., Uhr, J.W., Grant, L. (Eds.): Injury, Inflammation, and Immunity, pp. 183–210. Baltimore: The Williams & Wilkins Comp. 1964Google Scholar
  327. Sevitt, S., Bull, J.P., Cruikshank, C.N.D., Jackson, D.M., Lowbury, E.J.L.: Failure of an antihistamine drug to influence the course of experimental human burns. Brit. med. J. 1952 II, 57–59Google Scholar
  328. Sicuteri, F.: Bradykinin and intracranial circulation in man. In: Erdös, E.G. (Ed.): Bradykinin, Kallidin, and Kallikrein. Handb. exp. Pharmakol, Vol. XXV, pp. 482–515. Berlin-Heidelberg-New York: Springer 1970Google Scholar
  329. Sicuteri, F., Franchi, G., Bianco, P. L.D., Fanciollacci, M.: Some physiological and pathological roles of kininogen and kinins. In: Erdos, E.G., Back, N., Sicuteri, F. (Eds.): Hypotensive Peptides, pp. 522–535. Berlin-Heidelberg-New York: Springer 1966Google Scholar
  330. Sicuteri, F., Franchi, G., Fanciullacci, M., Del Bianco, P. L.: Serotonin-bradykinin potentiation of the pain-receptors in man. Life Sci. 4, 309–316 (1965)PubMedGoogle Scholar
  331. Souza, J.M., Rocha e Silva, M.: Possivel participação de cinina (bradicinina) no mecanismo do choque térmico em ratos. Ciênc. Cult. 19, 396 (1967)Google Scholar
  332. Souza, J.M., Rocha e Silva, M.: Novas evidências de participaçao da bradicinina no choque térmico de ratos. Ciênc. Cult. 20, 405 (1968)Google Scholar
  333. Sparrow, E.M., Wilhelm, D.L.: Species differences in susceptibility to capillary permeability factors histamine, 5-hydroxytryptamine and compound 48/80. J. Physiol. (Lond.) 137, 51–65 (1957)Google Scholar
  334. Spector, W.G., Willoughby, D.A.: Histamine and 5-hydroxytryptamine in acute experimental pleurisy. J. Path. Bac. 74, 57–65 (1957)Google Scholar
  335. Spector, W.G., Willoughby, D.A.: Experimental supression of the acute inflammatory changes of thermal injury. J. Path. Bact. 78, 121–132 (1959)PubMedGoogle Scholar
  336. Spector, W.G., Willoughby, D.A.: Salicylate and increased vascular permeability. Nature (Lond.) 196, 1104 (1962)Google Scholar
  337. Spector, W.G., Willoughby, D.A.: The effect of vascular permeability factors on emigration of leukocytes. J. Path. Bact. 87, 341–346 (1964)PubMedGoogle Scholar
  338. Spilberg, I., Osterland, C.K.: Anti-inflammatory effect of the trypsin-kallikrein inhibitor in acute arthritis induced by urate crystals in rabbits. J. Lab. clin. Med. 76, 472–479 (1970)PubMedGoogle Scholar
  339. Spragg, J., Austen, K.F.: The preparation of human kininogen. II. Further characterization of purified human kininogeN.J. Immunol. 107, 1512–1519 (1971)PubMedGoogle Scholar
  340. Starr, M.S., West, G.B.: Bradykinin and oedema formation in heated paws of rats. Brit. J. Pharmacol. 31, 178–187 (1967)PubMedGoogle Scholar
  341. Starr, M.S., West, G.B.: Further evidence for the involvement of kinin in anaphylactic shock in the rat. Brit. J. Pharmacol. 37, 178–184 (1969)Google Scholar
  342. Stewart, J.M., Woolley, D.W.: Bradykinin analogs. In: Rocha e Silva, M., Rothschild, H.A. (Eds.): International Symposium on Vaso-Active Polypeptides: Bradykinin and Related Kinins, pp. 7–13. São Paulo: Edart 1967Google Scholar
  343. Streeten, D.H.P., Kerr, C.B., Kerr, L.P., Prior, J.C., Dalakos, T.G.: Hyperbradykininism: a new orthostatic syndrome. Lancet 18, 1048–1053 (1972)Google Scholar
  344. Stürmer, E.: The influence of intra-arterial infusions of synthetic bradykinin on flow and composition of lymph in dogs. In: Erdos, E.G., Back, N., Sicuteri, F. (Eds.): Hypotensive Peptides, pp. 368–374. Berlin-Heidelberg-New York: Springer-Verlag 1966Google Scholar
  345. Stürmer, E., Berde, B.: A pharmacological comparison between synthetic bradykinin and kallidin. J. Pharmacol, exp. Ther. 139, 38–41 (1963)Google Scholar
  346. Stürmer, E., Cerletti, A.: Bradykinin. Amer. Heart J. 62, 149–154 (1961 a)PubMedGoogle Scholar
  347. Stürmer, E., Cerletti, A.: Das Bradykinin-Oedem der Rattenpfote. Helv. physiol. pharmacol. Acta 19, C 32-C 35 (1961b)Google Scholar
  348. Suzuki, T., Iwanaga, S., Sato, T., Nagasawa, S., Kato, H., Yano, M., Horiuchi, K.: Biochemical properties of kininogens and kinin-releasing enzymes. In: Rocha e Silva, M., Rothschild, H.A. (Eds.): International Symposium on Vaso-Active Polypeptides: Bradykinin and Related Kinins, pp. 27–33. São Paulo: Edart 1967Google Scholar
  349. Thal, A.P., Kobold, E.E., Holenberg, M.J.: The release of vasoactive substances in acute pancreatitis. Amer. J. Surg. 105, 708–713 (1963)PubMedGoogle Scholar
  350. Thomas, G., West, G. B.: Prostaglandins, kinin and inflammation in the rat. Brit. J. Pharmacol. 50, 231–235 (1974)Google Scholar
  351. Trapnell, J.E., Righby, C.C., Talbot, C.H., Duncan, H.L.: A controlled trial of trasylol in the treatment of acute pancreatitis. Brit. J. Surg. 61, 177–182 (1974)PubMedGoogle Scholar
  352. Ungar, G., Damgaard, E., Hummel, F. P.: Action of salicylates and related drugs on inflammation. Amer. J. Physiol. 171, 545–553 (1952)PubMedGoogle Scholar
  353. Urbanitz, D., Sailer, R., Habermann, E.: In vivo investigations on the role of the kinin system in tissue injury and shock syndromes. In: Sicuteri, E., Rocha e Silva, M., Back, N. (Eds.): Bradykinin and Related Kinins: Cardiovascular, Biochemical, and Neural Actions, pp. 343–354. New York-London: Plenum Press 1970Google Scholar
  354. Van Arman, C.G.: Interrelationship among some peptide precursors. In: Gaddum, J.H. (Ed.): Polypeptides Which Stimulate Plain Muscle, pp. 103–114. Edinburgh-London: Livingstone 1955Google Scholar
  355. Van Arman, C.G., Begany, A.J., Miller, L.M., Pless, H.H.: Some details of the inflammations caused by yeast and carrageenin. J. Pharmacol, exp. Ther. 150, 328–334 (1965)Google Scholar
  356. Van Arman, C.G., Carlson, R. P., Risley, E.A., Thomas, R.H., Nuss, G.W.: Inhibition effects of indomethacin, aspirin, and certain other drugs on inflammations induced in rat and dog by carrageenan, sodium urate and ellagic acid. J. Pharmacol, exp. Ther. 175, 459–468 (1970)Google Scholar
  357. Van Arman, C.G., Nuss, G.W.: Plasma bradykininogens levels in adjuvant arthritis and carrageenan inflammation. J. Path. 99, 245–250 (1969)PubMedGoogle Scholar
  358. Van Arman, C.G., Nuss, G.W., Winter, C.A., Flataker, L.: Proteolytic enzymes as mediators of pain: In: Lim, R.K.S., Armstrong, D., Pardo, E.G. (Eds.): Pharmacology of Pain, pp. 25–32. Oxford: Pergamon 1968Google Scholar
  359. Vane, J.R.: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (New Biol.) 231, 232–235 (1971)Google Scholar
  360. Vogel, R., Werle, E.: Kallikrein inhibitors. In: Erdös, E.G. (Ed.): Bradykinin, Kallidin, and Kallikrein. Handbook experimental Pharmacology, Vol. XXV, pp. 213–249. Berlin-Heidelberg-New York: Springer 1970Google Scholar
  361. Vogt, W.: Kinin formation by plasmin, an indirect process mediated by activation of kallikrein. J. Physiol. (Lond.) 170, 153–166 (1964)Google Scholar
  362. Vogt, W.: Demonstration of the presence of two separate kinin-forming systems in human and other plasma. In: Erdos, E.G., Back, N., Sicuteri, F. (Eds.): Hypotensive Peptides, pp. 185–197. Berlin-Heidelberg-New York: Springer 1966Google Scholar
  363. Vugman, I..: Alterações no teor de bradicininogênio do plasma do cobaio induzidas por choque adrenalinico. Ciênc. Cult. 15, 259–260 (1963)Google Scholar
  364. Waaler, B.A.: The effect of bradykinin in an isolated perfuzed dog lung preparation. J. Physiol. (Lond.) 157, 475–483 (1961)Google Scholar
  365. Ward, P.A.: Chemotactic factors for neutrophils, eosinophils, mononuclear cells and lymphocytes. In: Austen, K.F., Becker, E.L. (Eds.): Biochemistry of Acute Allergic Reaction, pp. 229–241. Oxford: Blackwell Scientific 1971Google Scholar
  366. Webster, M.E.: Human plasma kallikrein, its activation and pathological role. Fed. Proc. 27, 84–89 (1968)PubMedGoogle Scholar
  367. Webster, M.E.: Recommendations for nomenclature and units. In: Erdos, E.G. (Ed.): Bradykinin, Kallidin, and Kallikrein. Handb. exp. Pharmacology, Vol. XXV, pp. 659–665. Berlin-Heidelberg-New York: Springer 1970aGoogle Scholar
  368. Webster, M.E.: Kallikreins in glandular tissues. In: Erdös, E.G. (Ed.): Bradykinin, Kallidin, and Kallikrein. Handb. exp. Pharmakol. Vol. XXV, pp. 131–155. Berlin-Heidelberg-New York: Springer 1970 bGoogle Scholar
  369. Webster, M.E., Clark, W.R.: Significance of the kallikrein-kallidinogen-kallidin system in shock. Amer. J. Physiol. 197, 406–412 (1959)PubMedGoogle Scholar
  370. Webster, M.E., Guimãraes, J.A., Kaplan, A.P., Colman, R.W., Pierce, J.V.: Activation of surfacebound Hageman factor: pre-eminent role of high molecular weight kininogen and evidence for a new factor. Advanc. exp. Med. Biol. (1976) (in press)Google Scholar
  371. Webster, M.E., Guimaraes, J.A., Pierce, J.V.: High molecular weight kininogen: its role in activation of Hageman factor. In: Abstracts International Symposium on Vaso-peptides, Kinin 75, Fiesole: 1975Google Scholar
  372. Webster, M.E., Maling, H.M., Zweig, M.H., Williams, M.A., Anderson, W., Jr.: Urate crystal induced inflammation in the rat: evidence for the combined actions of kinins, histamine, and components of complement. Immunol. Commun. 1, 185–198 (1972)PubMedGoogle Scholar
  373. Webster, M.E., Pierce, J.V.: Studies on plasma kallikrein and its relationship to plasmin. J. Pharmacol, exp. Ther. 130, 484–491 (1960)Google Scholar
  374. Webster, M.E., Pierce, J.V.: Action of the kallikreins on synthetic ester substrates. Proc. Soc. exp. Biol. (N.Y.) 107, 186–191 (1961)Google Scholar
  375. Webster, M.E., Pierce, J.V.: The nature of the kallidins released from human plasma by kallikreins and other enzymes. Ann. N.Y. Acad. Sci. 104, 91–107 (1963)PubMedGoogle Scholar
  376. Webster, M.E., Ratnoff, O.D.: Role of Hageman factor in the activation of vasodilator activity in human plasma. Nature (Lond.) 192, 180–181 (1961)Google Scholar
  377. Weiss, A.S., Gallin, J.I., Kaplan, A.P.: Fletscher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. J. clin. Invest. 53, 622–633 (1974)PubMedGoogle Scholar
  378. Weissmann, G., Dingle, J.: Release of lysosomal protease by ultraviolet irradiation and inhibition by hydrocortisone. Exp. Cell Res. 25, 207–210 (1961)PubMedGoogle Scholar
  379. Weissmann, G., Fell, H. B.: The effect of hydrocortisone on the response of fetal rat skin in culture to ultraviolet irradiation. J. exp. Med. 116, 365–380 (1962)PubMedGoogle Scholar
  380. Weissmann, G., Thomas, L.: Studies on lysosomes. I. The effects of endotoxin, endotoxin tolerance, and cortisone on the release of acid hydrolases from a granular fraction of rabbit liveR.J. exp. Med. 116, 433–4150 (1962)PubMedGoogle Scholar
  381. Werle, E.: Über die Inaktivierung des Kallikreins. Biochem. Z. 273, 291–305 (1934)Google Scholar
  382. Werle, E.: Über Kallikrein aus Blut. Biochem. Z. 287, 235–261 (1936)Google Scholar
  383. Werle, E.: History of kallikrein and some aspects of its chemistry and physiology. In: Haberland, G.L., Rohen, J.W. (Eds.): Kininogenases. First Symposium on Physiological Properties and Pharmacological Rational, pp. 7–22. Stuttgart-New York: F. K. Schattauer 1973Google Scholar
  384. Werle, E., Appel, W.: Über einen Hemmkörper für Kallikrein und verschiedene Proteinasen aus Rinderleben. II Z. Naturforsch. 14B, 385–392 (1959)Google Scholar
  385. Werle, E., Erdös, E.G.: Über eine neue blutdrucksenkende, darm- und uteruserregende Substanz im menschlichen Urin. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 223, 234–243 (1954)Google Scholar
  386. Werle, E., Forell, M.M., Maier, L.: Zur Kenntnis der blutdrucksenkenden Wirkung des Trypsins. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 225, 369–380 (1955)Google Scholar
  387. Werle, E., Kaufmann-Boetsch, B.: Über esteratische Wirkungen von Kallikrein und Trypsin und ihre Hemmung durch Kallikrein- und Trypsininhibitoren. Hoppe-Seyler’s Z. physiol. Chem. 319, 52–63 (1960)PubMedGoogle Scholar
  388. Werle, E., Kehl, R., Koebke, K.: Über Trypsin, Chymotrypsin, Kallidin, und Bradykinin. Biochem. Z. 321, 213–220 (1950)PubMedGoogle Scholar
  389. Werle, E., Maier, L.: Über die chemische und pharmakologische Unterscheidung von Kallikreinen verschiedener Herkunft. Biochem. Z. 323, 279–283 (1952)PubMedGoogle Scholar
  390. Werle, E., Roden, P. von: Über das Vorkommen von Kallikrein in den Speicheldrüsen und im Mundspeichel. Biochem Z. 286, 213–219 (1936)Google Scholar
  391. Werle, E., Roden, P. von: Über das Vorkommen von Kallikrein in den Speicheldrüsen und im Mundspeichel und über eine blutdrucksteigernde Substanz in der Submaxillarisdrüse des Hundes. Biochem. Z. 301, 328–337 (1939)Google Scholar
  392. Werle, E., Trautschold, I., Leysath, G.: Isolierung und Struktur des Kallidins. Hoppe-Seyler’s Z. physiol. Chem. 326, 174–176 (1961)PubMedGoogle Scholar
  393. Werle, E., Vogel, R.: Über die Kallikreinausscheidung im Harn nach experimenteller Nierenschädigung. Arch. int. Pharmacodyn. 126, 171–186 (1960)PubMedGoogle Scholar
  394. Whitfield, J. F., MacManus, J.P., Gillan, D.J.: Giclic AMP mediation of bradykinin-induced stimulation of mitotic activity and DNA synthesis in thymocytes. Proc. Soc. exp. Biol. (N.Y.) 133, 1270–1274 (1970)Google Scholar
  395. Whittle, B. A.: Release of a kinin by intraperitoneal injection of chemical agents in mice. Int. J. Neuropharmacol. 3, 369–371 (1964)PubMedGoogle Scholar
  396. Wilhelm, D.L.: Kinins in human disease. Ann. Rev. Med. 22, 63–84 (1971)PubMedGoogle Scholar
  397. Wilhelm, D.L.: Chemical mediators. In: Zweifach, B.W., Grant, L., McCluskey, R.T. (Eds.): The Inflammatory Process, 2nd Ed., Vol. II, pp. 251–301. New York-London: Academic Press 1973Google Scholar
  398. Wilhelm, D.L., Mason, B.: Vascular permeability changes in inflammation: The role of endogenous permeability factors in mild thermal injury. Brit. J. exp. Path. 41, 487–506 (1960)PubMedGoogle Scholar
  399. Wilhelm, D.L., Mill, P.J., Sparrow, E.M., MacKay, M.E., Miles, A.A.: Enzyme-like globulins from serum reproducing the vascular phenomena of inflammation. IV. Activable permeability factor and its inhibitor in the serum of the rat and the rabbit. Brit. J. exp. Path. 39, 228–250 (1958)PubMedGoogle Scholar
  400. Willis, A.L.: Release of histamine, kinin, and prostaglandins during carrageenin-induced inflammation in the rat. In: Mantegazza, P., Horton, E.W. (Eds.): Prostaglandins, peptides and amines, pp. 31–38. New York: Academic 1969Google Scholar
  401. Winter, C.A., Flataker, L.: Reaction thresholds to pressure in edematous hindpaws of rats and responses to analgesic drugs. J. Pharmacol, exp. Ther. 150, 165–171 (1965)Google Scholar
  402. Winter, C.A., Nuss, G.W.: Treatment of adjuvant arthritis in rats with anti-inflammatory drugs. Arthr. Rheum. 9, 394–404 (1966)Google Scholar
  403. Winter, C.A., Risley, E.A., Nuss, G.W.: Carrageenin-induced edema in hindpaw of the rat as an assay for anti-inflammatory drugs. Proc. Soc. exp. Biol. (N.Y.) 111, 544–547 (1962)Google Scholar
  404. Woessner, J.F. Jr.: Lysosomal enzymes and connective tissue breakdown. In: Bertelli, A., Houck, J.C. (Eds.): Inflammation Biochemistry and Drug Interaction, pp. 122–130. Amsterdam: Excerpta Medica Foundation 1969Google Scholar
  405. Wuepper, K.D.: Prekallikrein deficiency in man. J. exp. Med. 138, 1345–1355 (1973)PubMedGoogle Scholar
  406. Wuepper, K.D., Lawrence, T.G., Cochrane, C.G.: Proenzyme components of the plasma kinin system. J. clin. Invest. 49, 105a (1970a)Google Scholar
  407. Wuepper, K.D., Miller, D.R., Lacombe, M.J.: Flaujeac trait: deficiency of kininogen in man. Fed. Proc. 34, 859 (1975)Google Scholar
  408. Wuepper, K.D., Tucker III., E.S., Cochrane, C.G.: Plasma kinin system: Proenzyme components. J. Immunol. 105, 1307–1311 (1970 b)Google Scholar
  409. Yang, H.Y.T., Erdös, E.G.: Second kininase in human blood plasma. Nature (Lond.) 215, 1402–1403 (1967)Google Scholar
  410. Yano, M., Nagasawa, S., Horiuchi, K., Suzuki, T.: Separation of a new substrate, kininogen I, for plasma kallikrein in bovine plasma. J. Biochem. (Tokyo) 62, 504–506 (1967)Google Scholar
  411. Zuber, M., Sache, E.: Isolation and characterization of porcine pancreatic kallikrein. Biochemistry 13, 3098–3110 (1974)PubMedGoogle Scholar
  412. Zweifach, B.W.: Microcirculatory aspects of tissue injury. Ann. N.Y. Acad. Sci. 116, 831–838 (1964)PubMedGoogle Scholar
  413. Zweifach, B.W.: Microcirculatory effects of polypeptides. In: Erdos, E.G., Back, N., Sicuteri, F. (Eds.): Hypotensive Polypeptides, pp. 451–462. Berlin-Heidelberg-New York: Springer 1966Google Scholar
  414. Zweifach, B.W., Nagler, A.L., Troll, W.: Some effects of proteolytic inhibitors on tissue injury and systemic anaphylaxis. J. exp. Med. 113, 437–450 (1961)PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1978

Authors and Affiliations

  • J. Garcia Leme

There are no affiliations available

Personalised recommendations